• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Coronavirus News Roundup: AstraZeneca Vaccine Moves to Phase 3 Trial, Survey Shows Most Pharmacists Plan to Administer COVID-19 Vaccine


Here's this week's coronavirus-related news.


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has infected an estimated 26,123,176 individuals worldwide, and approximately 6.1 million Americans. The latest COVID-19 related news includes AstraZeneca’s investigational vaccine expanding into a phase 3 clinical trial and a survey by NCPA gauging pharmacy plans for administering a COVID-19 vaccine.

Here’s a roundup of the latest coronavirus-related news:

COVID-19 Vaccine AZD1222 Moves to US Phase 3 Trial

AstraZeneca’s investigational COVID-19 vaccine candidate, AZD1222, has expanded into a phase 3 clinical trial, according to a press release.

The US trial, called D8110C00001, is funded by the Biomedical Advanced Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). The NIAID-supported COVID-19 Prevention Network will participate in the trial.

Read more

Survey: Most Pharmacies Polled Plan to Administer COVID-19 Vaccines

A new survey conducted by NCPA suggests that most pharmacies plan to offer a COVID-19 immunization service when a vaccine becomes available.

Eighty-six percent of respondents said they plan to offer the COVID-19 vaccines in their pharmacies when they hit the marketplace, according to the survey of nearly 800 community pharmacy owners/managers.

Read more

FDA Issues Emergency Use Authorization to New 15-Minute COVID-19 Antigen Test

Officials with the FDA have issued Emergency Use Authorization (EUA) for Abbott’s BinaxNOW COVID-19 Ag Card rapid test for the detection of COVID-19, according to a press release.

BinaxNOW delivers results in 15 minutes and will be sold for $5, Abbott said. The test, which is approximately the size of the credit card, is highly portable and easy to use, with no equipment required.

Read more

Related Videos
© 2023 MJH Life Sciences

All rights reserved.